London, UK and Boxmeer, The Netherlands; 26 September 2007 - Protherics PLC
("Protherics" or the "Company"), the international biopharmaceutical company
focused on critical care and cancer, and Nobilon International B.V. ("Nobilon"),
part of Organon, the human health care business unit of Akzo Nobel, today
announced that Nobilon has licensed Protherics' CoVaccine HT(TM) adjuvant for
use in pandemic influenza vaccines and seasonal influenza vaccines in elderly
people.
